A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.
465 - 475
J Med Genet
MetadataShow full item record
BACKGROUND: Although BRCA1 and BRCA2 mutations account for only ∼27% of the familial aggregation of ovarian cancer (OvC), no OvC risk prediction model currently exists that considers the effects of BRCA1, BRCA2 and other familial factors. Therefore, a currently unresolved problem in clinical genetics is how to counsel women with family history of OvC but no identifiable BRCA1/2 mutations. METHODS: We used data from 1548 patients with OvC and their relatives from a population-based study, with known BRCA1/2 mutation status, to investigate OvC genetic susceptibility models, using segregation analysis methods. RESULTS: The most parsimonious model included the effects of BRCA1/2 mutations, and the residual familial aggregation was accounted for by a polygenic component (SD 1.43, 95% CI 1.10 to 1.86), reflecting the multiplicative effects of a large number of genes with small contributions to the familial risk. We estimated that 1 in 630 individuals carries a BRCA1 mutation and 1 in 195 carries a BRCA2 mutation. We extended this model to incorporate the explicit effects of 17 common alleles that are associated with OvC risk. Based on our models, assuming all of the susceptibility genes could be identified we estimate that the half of the female population at highest genetic risk will account for 92% of all OvCs. CONCLUSIONS: The resulting model can be used to obtain the risk of developing OvC on the basis of BRCA1/2, explicit family history and common alleles. This is the first model that accounts for all OvC familial aggregation and would be useful in the OvC genetic counselling process.
AuthorsJervis, S; Song, H; Lee, A; Dicks, E; Harrington, P; Baynes, C; Manchanda, R; Easton, DF; Jacobs, I; Pharoah, PPD; Antoniou, AC
- College Publications 
Showing items related by title, author, creator and subject.
WS57: Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research (14-Oct-2014) History of Twentieth Century Medicine Group; History of Modern Biomedicine Research Group; Farnetti T (2017-06-06)Selection of photos taken at the Witness Seminar “Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research" held by the History of Modern Biomedicine Research Group, 14-Oct-2014. Participants: ...
History of Twentieth Century Medicine Group; History of Modern Biomedicine Research Group (2017-05-31)Selection of photos taken at the Witness Seminar “Clinical Genetics in Britain: Origins and development” held by the History of Twentieth Century Medicine Group, 23-Sep-2008. Participants: Ms Chris Barnes, Dr Caroline ...
Disanto, G; Sandve, GK; Berlanga-Taylor, AJ; Morahan, JM; Dobson, R; Giovannoni, G; Ramagopalan, SV (2012)More than 50 genomic regions have now been shown to influence the risk of multiple sclerosis (MS). However, the mechanisms of action, and the cell types in which these associated variants act at the molecular level remain ...